CL2008001074A1 - Uso de compuestos de triazol, antagonistas de smo para tratar cancer. - Google Patents

Uso de compuestos de triazol, antagonistas de smo para tratar cancer.

Info

Publication number
CL2008001074A1
CL2008001074A1 CL2008001074A CL2008001074A CL2008001074A1 CL 2008001074 A1 CL2008001074 A1 CL 2008001074A1 CL 2008001074 A CL2008001074 A CL 2008001074A CL 2008001074 A CL2008001074 A CL 2008001074A CL 2008001074 A1 CL2008001074 A1 CL 2008001074A1
Authority
CL
Chile
Prior art keywords
treat cancer
triazole compounds
smo antagonists
smo
antagonists
Prior art date
Application number
CL2008001074A
Other languages
English (en)
Spanish (es)
Inventor
James M Balkovec
Sherman T Waddell
Rolf Thieringer
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CL2008001074A1 publication Critical patent/CL2008001074A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2008001074A 2007-04-18 2008-04-15 Uso de compuestos de triazol, antagonistas de smo para tratar cancer. CL2008001074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92501807P 2007-04-18 2007-04-18

Publications (1)

Publication Number Publication Date
CL2008001074A1 true CL2008001074A1 (es) 2009-06-05

Family

ID=39433852

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001074A CL2008001074A1 (es) 2007-04-18 2008-04-15 Uso de compuestos de triazol, antagonistas de smo para tratar cancer.

Country Status (12)

Country Link
US (1) US7691887B2 (enExample)
EP (1) EP2136803B1 (enExample)
JP (1) JP5498936B2 (enExample)
CN (1) CN101663033B (enExample)
AR (1) AR066063A1 (enExample)
AT (1) ATE555785T1 (enExample)
AU (1) AU2008241527B2 (enExample)
CA (1) CA2683946C (enExample)
CL (1) CL2008001074A1 (enExample)
PE (1) PE20090806A1 (enExample)
TW (1) TW200901987A (enExample)
WO (1) WO2008130552A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
CA2710377A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
EP2334683B1 (en) * 2008-08-29 2017-03-22 MSD Italia S.r.l. Saturated bicyclic heterocyclic derivatives as smo antagonists
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
AU2010321773A1 (en) * 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3，3-二氟环丁烷甲酸的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
DE60317631T2 (de) 2002-02-01 2008-09-25 Merck & Co., Inc. 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
CN1795181A (zh) 2003-05-29 2006-06-28 麦克公司 用作11β－羟基类固醇脱氢酶－1抑制剂的三唑衍生物
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2006078283A2 (en) 2004-04-30 2006-07-27 Genentech, Inc. Quinoxaline inhibitors of hedgehog signalling
EP1797034B1 (en) 2004-08-06 2010-06-30 Merck Sharp & Dohme Corp. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
BRPI0514444A (pt) 2004-08-27 2008-06-10 Infinity Pharmaceuticals Inc análogos de ciclopamina e métodos de uso destes
KR20160058972A (ko) 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
CN101083996A (zh) 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
CA2587489C (en) 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
NI200800069A (es) 2005-10-20 2008-06-25 Merck & Co Inc Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1

Also Published As

Publication number Publication date
PE20090806A1 (es) 2009-06-27
CA2683946A1 (en) 2008-10-30
ATE555785T1 (de) 2012-05-15
AR066063A1 (es) 2009-07-22
AU2008241527A1 (en) 2008-10-30
US7691887B2 (en) 2010-04-06
TW200901987A (en) 2009-01-16
CN101663033A (zh) 2010-03-03
EP2136803A1 (en) 2009-12-30
JP5498936B2 (ja) 2014-05-21
AU2008241527B2 (en) 2014-02-13
CN101663033B (zh) 2013-01-16
US20080262051A1 (en) 2008-10-23
EP2136803B1 (en) 2012-05-02
JP2010524937A (ja) 2010-07-22
CA2683946C (en) 2013-01-22
WO2008130552A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
CL2008001074A1 (es) Uso de compuestos de triazol, antagonistas de smo para tratar cancer.
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201171367A1 (ru) Винилиндазолильные соединения
TN2010000071A1 (en) Fused imidazoles or cancer treatment
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
BR112012011086A2 (pt) uso de betanecol para o tratamento de xerostomia
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
BRPI0914555A2 (pt) derivados de triazol bicíclicos para o tratamento de tumores
MA32900B1 (fr) Compose d'aminopyrazole
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
PA8843901A1 (es) INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
CR11412A (es) Inhibidores de cinesina como productos terapeuticos para el cancer
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
EA201000258A1 (ru) Новые гербициды
CR20120502A (es) Uso de nuevos inhibidores de pan-cdk para tratar tumores
HN2009003466A (es) Herbicidas novedosos
MA33059B1 (fr) Utilisation d'antagonistes des recepteurs nk
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
BR112018008025A2 (pt) inibidores de pdk1 heterocíclicos para uso no trata-mento de câncer
IN2012DN01223A (enExample)